Bivalirudin: An anticoagulant for acute coronary syndromes and coronary interventions

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 6, 2002, Pages 777-788

  White, Harvey D ^a   Chew, Derek P ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

Acute coronary syndromes; Acute myocardial infarction; Angioplasty; Anticoagulant; Bivalirudin; Percutaneous coronary intervention; Thrombin inhibitor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; WARFARIN; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE DISEASE; ACUTE HEART INFARCTION; ANXIETY NEUROSIS; BACKACHE; BLEEDING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG POTENCY; DRUG SAFETY; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; INJECTION PAIN; INSOMNIA; LEECH; NEW ZEALAND; PELVIS PAIN SYNDROME; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT INDICATION; UNITED STATES; URINE RETENTION; ANGINA PECTORIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DRUG ADMINISTRATION; DRUG INTERACTION; HEART INFARCTION; METHODOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS;

EID: 0036078523     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.6.777     Document Type: Review

References (43)

1. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomised trial
2. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
3. Clinical outcomes of bivalirudin for ischemic heart disease
4. Ex vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin
5. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
6. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
7. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
8. LMW heparin (dalteparin) for improvement of patency after thrombolysis in AMI: A prospective randomized multi-centre coronary angiography study
9. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
10. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction: The AMI-SK study
11. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
12. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
13. The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombinmediated platelet aggregation
14. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans
15. Hirulog: A direct thrombin inhibitor for management of acute coronary syndromes
16. The use of bivalirudin in patients with renal impairment
17. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction
18. Hirulog in the treatment of unstable angina: Results of the Thrombin Inhibition in Myocardial Ischaemia (TIMI) 7 Trial
19. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
20. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction
21. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
22. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction
23. Heparin variability and resistance: Comparison with a direct thrombin inhibitor
24. Preclinical and clinical studies on hirulog: A potent and specific direct thrombin inhibitor
25. Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris
26. Initial experience with a direct antithrombin, hirulog, in unstable angina: Anticoagulant, antithrombotic and clinical effects
27. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI-8 trial
28. Improved efficacy and less bleeding: Further evidence of a unique uncoupling of benefit and risk with bivalirudin
29. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease
30. Bivalirudin for percutaneous coronary interventions: Development perspective
31. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
32. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study
33. A second look at bivalirudin
34. Cost analysis of bivalirudin in percutaneous coronary intervention
35. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge
36. Early reinfarction after fibrinolysis: Experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies to Coronary Arteries (GUSTO III) Trials
37. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients
38. Antithrombin, antiplatelet therapy or both during PCI: A preliminary randomized trial
39. The REPLACE 1 Trial: A pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade
40. Thrombolysis in Myocardial Infarction (TIMI) Trial-Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
41. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention
42. Direct thrombin inhibition by bivalirudin compared with abciximab, a GPIIb/IIIa antagonist, during percutaneous coronary intervention: Favorable hemostatic profile compared to heparin/abciximab
43. Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal and early ambulation: A feasibility study with implications for day-stay